The 2025 targets include achieving around €62 billion in revenues, falling costs in absolute terms, a stable cost of risk, ...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer ...

The Annual Report 2024 and the Statement of the mandatory review of Corporate Governance, cf. section 107b of the Danish Financial Statement Act, is attached to this announcement. Anita Nassar Pradeep ...

Revenue for the twelve months ended December 31, 2024, was $4.9 million, compared to $15.5 million for the twelve months ended December 31, 2023, primarily reflecting a decrease in construction ...